sacituzumab
gilead sciences
['breast', 'tropics02', 'sacituzumab', 'sacitu, govi']
at #esmo22 presented the os data (ia2) of #tropics02 trial: sacituzumab govitecan is associated with longer os over tpc ( ~3 mos, hr 0.79) in pretreated patients with hr+,her2-neg #breastcancer. 
MD, Medical Oncologist????•Research Fellow at @JulesBordet Institute in Brussels???? Great interest in #BreastCancer and #ImmunoOncology